Severe Hypoglycemia

A dangerous condition where blood glucose falls to critically low levels (<54 mg/dL), causing cognitive impairment, loss of consciousness, seizures, or coma. Requires external assistance for treatment and is a medical emergency in diabetes management.

Quick Answer

What it is

A dangerous condition where blood glucose falls to critically low levels (<54 mg/dL), causing cognitive impairment, loss of consciousness, seizures, or coma. Requires external assistance for treatment and is a medical emergency in diabetes management.

Key findings

  • Grade A: Glucose Recovery (Glucagon (GlucaGen/Gvoke/Baqsimi))
  • Grade A: Time to Recovery (Glucagon (GlucaGen/Gvoke/Baqsimi))
  • Grade A: Symptom Relief (Glucagon (GlucaGen/Gvoke/Baqsimi))

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

ℹ️ Quick Facts

Quick Facts: Severe Hypoglycemia

  • Supplements Studied:1
1 supps · 4 outcomes

Detailed Outcomes

A
Glucose Recovery
99-100% achieve glucose >70 mg/dL within 30 min. Median time 10-13 min. Non-inferior across all delivery methods (IM, SC, nasal).
large↑Improves
A
Time to Recovery
Median 10-12 min to plasma glucose recovery. Dasiglucagon: 65% recover within 10 min. Nasal: 11-16 min mean time to success.
large↓Improves
A
Symptom Relief
Rapid resolution of neuroglycopenic symptoms. Return of consciousness within 15-20 minutes in most patients.
large↑Worsens
A
Treatment Success Rate
Phase 3: 100% success in children, 99% in adults. Autoinjector non-inferior to emergency kit. Nasal non-inferior to IM injection.
large↑Improves

Research Citations (42)

Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, metabolic dysfunction-associated steatotic liver disease, and other cardio-kidney-metabolic conditions.
(2025)
PMID: 41025406
Glucagon in metabolic disease: a mini-review of emerging multi-organ roles beyond glycemic control.
(2025)
PMID: 40822953
Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis.
(2025)
PMID: 40834249
Variable glucagon metabolic actions in diverse mouse models of obesity and type 2 diabetes.
(2024)
PMID: 39536823
Glucagon
(2023)
PMID: 29939616
A physiologic increase in brain glucagon action alters the hepatic gluconeogenic/glycogenolytic ratio but not glucagon's overall effect on glucose production.
(2023)
PMID: 36652399
Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies
(2022)
PMID: 34620618
Dasiglucagon Effectively Mitigates Postbariatric Postprandial Hypoglycemia: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial
(2022)
PMID: 35320361
Regulation of Hepatic Lipid and Glucose Metabolism by INSP3R1.
(2022)
PMID: 35657697
Glucagon receptor antagonism impairs and glucagon receptor agonism enhances triglycerides metabolism in mice.
(2022)
PMID: 36400402